266 related articles for article (PubMed ID: 31399497)
1. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
2. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
3. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
4. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
5. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
7. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
[TBL] [Abstract][Full Text] [Related]
8. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms.
Van Ravenstein SX; Mehta KP; Kavlashvili T; Byl JAW; Zhao R; Osheroff N; Cortez D; Dewar JM
EMBO J; 2022 Jun; 41(12):e110632. PubMed ID: 35578785
[TBL] [Abstract][Full Text] [Related]
10. Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
Karapetian M; Tsikarishvili S; Kulikova N; Kurdadze A; Zaalishvili G
DNA Repair (Amst); 2020 Mar; 87():102772. PubMed ID: 31877465
[TBL] [Abstract][Full Text] [Related]
11. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
14. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
[TBL] [Abstract][Full Text] [Related]
16. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
17. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
18. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
19. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
20. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
